Analyst Cuts Alkermes Rating As Cancer Drug Seems Less Effective Than Competitor
February 22, 2018 at 14:44 PM EST
Shares of Alkermes are sliding after Jefferies analyst Biren Amin downgraded the stock to Hold as he believes the shares are fairly valued.